Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharmaceuticals Inc.

Roderick S Davis

William R Ewing

Alfred P Spada

Heinz W Pauls

Yong Mi Choi-Sledeski

Michael R Becker

Daniel G McGarry

Christopher J Burns

Timothy Francis Gallagher

Wei He

Michael R Myers

Stephen M Condon

Kent W Neuenschwander

Joseph M Karpinski

Robert D Groneberg

Robert L Morris

Aiwen Li

Gregory Bernard Poli

Barbara Hanney

Jean-Francois Sabuco

John Ziqi Jiang

Mark A Bobko

Wan F Lau

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Substituted sulfonic acid

Growing community of inventors

West Chester, PA, United States of America

Roderick S Davis